Eric J. Small
Prostate cancer trialist who helped bring abiraterone and sipuleucel-T to patients, and led ASCO in 2025-26.
Medical oncologist whose trials underpinned approvals in castration-resistant prostate cancer, including the phase 3 sipuleucel-T and abiraterone studies. Served as ASCO president for the 2025-2026 term.
| Title | Journal | Year |
|---|---|---|
| Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Journal of Clinical Oncology | 2006 |
| Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer | Annals of Oncology | 2019 |
Pages like this
not linked directly; found by shared links- PersonRahul Aggarwal
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Androgen receptor, Prostate cancer.
- InstitutionSidney Kimmel Comprehensive Cancer Center at Jefferson Health
Shares Androgen receptor, Prostate cancer.
- PersonThomas A. Hope
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Prostate cancer.
- ProductMasofaniten
Shares Androgen receptor, Prostate cancer.
- PersonHoward I. Scher
Shares Androgen receptor, Prostate cancer.
- ProductBicalutamide
Shares Androgen receptor, Prostate cancer.
- ProductApalutamide
Shares Androgen receptor, Prostate cancer.
- ProductGallium-68 gozetotide (PSMA-11)
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Prostate cancer.